Robert W. Baird Has Lowered Expectations for ICON Public (NASDAQ:ICLR) Stock Price

ICON Public (NASDAQ:ICLR) had its target price lowered by stock analysts at Robert W. Baird from $221.00 to $203.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s price target points to a potential upside of 11.26% from the stock’s previous close.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. cut their target price on ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Barclays cut their price objective on ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a research note on Friday, February 21st. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 target price (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. William Blair reiterated an “outperform” rating on shares of ICON Public in a report on Tuesday, January 14th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $263.00 price objective on shares of ICON Public in a research note on Wednesday, January 15th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $279.17.

ICON Public Trading Down 1.3 %

NASDAQ:ICLR opened at $182.45 on Tuesday. The company has a market capitalization of $14.73 billion, a P/E ratio of 19.16, a P/E/G ratio of 1.86 and a beta of 1.19. The stock’s 50 day moving average price is $201.37 and its 200 day moving average price is $239.26. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. ICON Public has a 52 week low of $179.50 and a 52 week high of $347.72.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.41 by $0.01. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. On average, research analysts forecast that ICON Public will post 13.38 EPS for the current fiscal year.

Institutional Investors Weigh In On ICON Public

A number of institutional investors have recently bought and sold shares of the business. Sierra Ocean LLC bought a new position in shares of ICON Public during the 4th quarter worth about $29,000. Park Place Capital Corp raised its position in ICON Public by 281.4% in the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after purchasing an additional 166 shares in the last quarter. Private Trust Co. NA lifted its stake in ICON Public by 48.8% during the fourth quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after purchasing an additional 82 shares during the period. GAMMA Investing LLC boosted its holdings in ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after purchasing an additional 169 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its stake in shares of ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.